You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
AstraZeneca
McKesson
Johnson and Johnson
Moodys

Last Updated: January 22, 2021

DrugPatentWatch Database Preview

Patent: 7,915,263

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,915,263
Title:Aminopyridine derivatives having aurora A selective inhibitory action
Abstract: The present invention relates to a compound of formula I: ##STR00001## wherein: R.sub.1 is a hydrogen atom, F, CN, etc.; R.sub.1\' is a hydrogen atom or lower alkyl which may be substituted; R.sub.2 is O, S, SO, SO.sub.2, etc.; R.sub.3 is a phenyl which may be substituted; X.sub.1, X.sub.2, and X.sub.3 each independently CH, N, etc. provided, however, that among X.sub.1, X.sub.2 and X.sub.3, the number of nitrogen is 0 or 1; W is the following residue: ##STR00002## wherein: W.sub.1, W.sub.2, and W.sub.3 each independently CH, N, etc., or a pharmaceutically acceptable salt or ester thereof.
Inventor(s): Iwasawa; Yoshikazu (Tsukuba, JP), Kato; Tetsuya (Tsukuba, JP), Kawanishi; Nobuhiko (Moriya, JP), Masutani; Kouta (Tsukuba, JP), Mita; Takashi (Tsukuba, JP), Nonoshita; Katsumasa (Tsukuba, JP), Ohkubo; Mitsuru (Ushiku, JP)
Assignee: Banyu Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:11/897,272
Patent Claims:see list of patent claims

Details for Patent 7,915,263

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Banyu Pharmaceutical Co., Ltd. (Tokyo, JP) 2026-08-31 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Banyu Pharmaceutical Co., Ltd. (Tokyo, JP) 2026-08-31 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Banyu Pharmaceutical Co., Ltd. (Tokyo, JP) 2026-08-31 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Banyu Pharmaceutical Co., Ltd. (Tokyo, JP) 2026-08-31 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Banyu Pharmaceutical Co., Ltd. (Tokyo, JP) 2026-08-31 RX search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial Banyu Pharmaceutical Co., Ltd. (Tokyo, JP) 2026-08-31 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,915,263

Country Patent Number Estimated Expiration
South Africa 200900126   Start Trial
World Intellectual Property Organization (WIPO) 2008026768   Start Trial
World Intellectual Property Organization (WIPO) 2008026769   Start Trial
United States of America 2008058347   Start Trial
United States of America 2010016335   Start Trial
Ukraine 95972   Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Harvard Business School
Merck
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.